Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients
Status:
Terminated
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
Pharmacological therapies of proven efficacy in coronavirus disease 2019 (COVID-19) are still
lacking.
Since two clinical stages of COVID-19 are emerging, an early one with typical clinical
characteristics of a viral infection (fever, malaise, cough) and a later one with pneumonia
leading to progressive respiratory failure, associated with heavy, cytokine-mediated,
inflammation, an intervention by a compound possessing both antiviral activity and
immunomodulatory effects would be most effective at the earliest possible stage.
The purpose of this clinical trial is to test the efficacy of Interferon-β-1a (IFNβ-1a), in
COVID-19 patients in an open label, randomized clinical trial.
The design of the study is to test IFNβ-1a in addition to standard of care compared with
standard of care alone.
The primary outcome is the time to negative conversion of Severe Acute Respiratory
Syndrome-CoronaVirus-2 (SARS-CoV-2) nasopharyngeal swabs.